Can you provide the last earnings date for TALIS BIOMEDICAL CORP?
TALIS BIOMEDICAL CORP (TLIS) last reported earnings on 8/7/2024.
NASDAQ:TLIS • US87424L2079
Past quarterly earnings results for TALIS BIOMEDICAL CORP (TLIS), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q2 2024 | -6.03 | - | -750.36% | - | -100.00% | |||
| Q1 2024 | -6.71 | - | 32.21% | 73K | - | -93.25% | ||
| Q4 2023 | -6.81 | - | 54.58% | 195K | 102K | 91.18% | -24.12% | |
| Q3 2023 | -8.62 | -7.52 | -14.67% | 41.36% | 140K | 102K | 37.25% | -82.41% |
| Q2 2023 | -0.71 | - | 95.32% | 581K | 51K | 1,039.22% | 1.57% | |
| Q1 2023 | -9.90 | -11.17 | 11.36% | 47.20% | 1.081M | 255K | 323.92% | -66.08% |
| Q4 2022 | -15.00 | -10.48 | -43.12% | 20.63% | 257K | 816K | -68.50% | -70.05% |
| Q3 2022 | -14.70 | -11.93 | -23.18% | -886.58% | 796K | 312.803K | 154.47% | 265.14% |
| Q2 2022 | -15.15 | -12.32 | -23.01% | -503.59% | 572K | 714K | -19.89% | 388.89% |
| Q1 2022 | -18.75 | -18.05 | -3.86% | -306.72% | 3.187M | 663K | 380.69% | -54.47% |
| Q4 2021 | -18.90 | -19.63 | 3.74% | 9.31% | 858K | 1.36M | -36.91% | 268.24% |
| Q3 2021 | -1.49 | -1.43 | -4.34% | - | 218K | 1.489M | -85.36% | -97.70% |
| Q2 2021 | -2.51 | -0.93 | -169.67% | - | 117K | - | -85.73% | |
| Q1 2021 | -4.61 | -0.77 | -502.61% | - | 7M | 5.75M | 21.74% | 1,654.39% |
| Q4 2020 | -20.84 | -0.80 | -2,502.72% | - | 233K | 1.937M | -87.97% | - |
| Q3 2020 | - | - | 9.486M | - | - | |||
| Q2 2020 | - | - | 820K | - | - | |||
| Q1 2020 | - | - | 399K | - | - |
Notes
TALIS BIOMEDICAL CORP (TLIS) last reported earnings on 8/7/2024.
TALIS BIOMEDICAL CORP (TLIS) missed EPS estimates and missed revenue estimates in the most recent quarter.